Nivolumab Plus Talazoparib Does Not Induce Responses in Heavily Pretreated Melanoma
Source: OncLive, April 2024
Nivolumab plus talazoparib did not produce RECIST-based tumor responses in heavily pretreated patients with unresectable or metastatic melanoma.
Treatment with nivolumab (Opdivo) in combination with talazoparib (Talzenna) did not lead to RECIST-based tumor responses in patients with unresectable or metastatic melanoma who have mutations in the BRCA or BRCA-ness genes, according to data from a phase 2 study (NCT04187833) presented at the 2024 AACR Annual Meeting.
All 7 patients with relapsed/refractory, heavily pretreated melanoma, who were enrolled in the study experienced disease progression within 6 months of treatment initiation, as assessed by RECIST criteria. The median duration of treatment was 12 weeks (range, 6-36).